TOFACITINIB IN THE TREATMENT OF SEVERE AND REFRACTORY BEHCET'S DISEASE: A SINGLECENTRE EXPERIENCE IN CHINA

被引：0
|
作者：
Liu, J. [1 ]
Sun, L. [1 ]
Zhang, F. [1 ]
Zheng, W. [1 ]
机构：
[1] Peking Union Med Coll & Chinese Acad Med Sci, Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DI, Key Lab Rheumatol & Clin Immunol, Peking Union Med Coll Hosp,Dept Rheumatol & Clin, Beijing, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.2802
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0326
引用
收藏
页码：389 / 389
页数：1
相关论文
共 50 条
  • [1] Tocilizumab in the Treatment of Severe and/or Refractory Behcet's Disease: a Single-Centre Experience in China
    Zheng, Wenjie
    Ding, Yanxia
    Wu, Di
    Zhou, Jiaxin
    Liu, JinJing
    Yan, Dong
    Zhou, Mengyu
    Zhao, Yan
    Zhang, Fengchun
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [2] GOLIMUMAB IN THE TREATMENT OF SEVERE AND/OR REFRACTORY VASCULO-BEHCET'S DISEASE: A SINGLE-CENTRE EXPERIENCE IN CHINA
    Sun, L.
    Liu, J.
    Zheng, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1558 - 1559
  • [3] Tocilizumab in the treatment of severe and/or refractory vasculo-Behcet's disease: a single-centre experience in China
    Zheng, W. J.
    Ding, Y. X.
    Li, C. R.
    Liu, J. J.
    Yu, X.
    Shi, J.
    Wang, Y. N.
    Zhao, Y.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (06) : S174 - S174
  • [4] Tocilizumab in the treatment of severe and/or refractory vasculo-Behcet's disease: a single-centre experience in China
    Ding, Yanxia
    Li, Chaoran
    Liu, Jinjing
    Yu, Xin
    Wang, Yining
    Shi, Jing
    Li, Lu
    Zhou, Jiaxin
    Wang, Li
    Chen, Hua
    Zhao, Yan
    Zheng, Wenjie
    RHEUMATOLOGY, 2018, 57 (11) : 2057 - 2059
  • [5] Gastrointestinal: Refractory parastomal ulcers of Behcet's disease responsive to tofacitinib
    Lin, M.
    Tang, J.
    Huang, Z.
    Gao, X.
    Chao, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 (04) : 485 - 485
  • [6] TOCILIZUMAB FOR SEVERE/REFRACTORY VASCULAR BEHCET'S DISEASE
    Zheng, W.
    Ding, Y.
    Liu, J.
    Shi, J.
    Li, C.
    Zhao, Y.
    Zeng, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1495 - 1496
  • [7] A pilot study of tofacitinib for refractory Behcet's syndrome
    Liu, Jinjing
    Hou, Yunxia
    Sun, Luxi
    Li, Chaoran
    Li, Lu
    Zhao, Yan
    Zeng, Xiaofeng
    Zhang, Fengchun
    Zheng, Wenjie
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (11) : 1517 - +
  • [8] BARICITINIB FOR THE TREATMENT OF REFRACTORY VASCULAR BEHCET'S DISEASE: A PILOT STUDY IN CHINA
    Wang, Z.
    Wang, X.
    Liu, J.
    Zhang, L.
    Zheng, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1568 - 1568
  • [9] Infliximab treatment in refractory vascular Behcet's disease: A single-center experience
    Kehribar, Demet Yalcin
    Ozgen, Metin
    VASCULAR, 2020, 28 (06) : 829 - 833
  • [10] Tofacitinib as an alternative therapy for refractory intestinal Behcet's syndrome
    Zou, Jun
    Cai, Jian-fei
    Ye, Jing-fen
    Guan, Jian-Long
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
12345